HC Wainwright Comments on Sage Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Sage Therapeutics in a note issued to investors on Friday, April 26th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.62) for the quarter. HC Wainwright currently has a "Neutral" rating and a $25.00 price objective on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.49) per share. HC Wainwright also issued estimates for Sage Therapeutics' Q2 2025 earnings at ($1.59) EPS, Q3 2025 earnings at ($1.13) EPS and Q4 2025 earnings at ($1.15) EPS.

SAGE has been the subject of several other research reports. The Goldman Sachs Group reduced their price objective on shares of Sage Therapeutics from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Scotiabank dropped their target price on shares of Sage Therapeutics from $34.00 to $19.00 and set a "sector outperform" rating on the stock in a report on Thursday, April 18th. Oppenheimer dropped their target price on shares of Sage Therapeutics from $25.00 to $17.00 and set a "market perform" rating on the stock in a report on Thursday, April 18th. Finally, Wedbush reiterated a "neutral" rating and issued a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $37.72.

Sage Therapeutics Price Performance

Shares of SAGE stock traded up $0.49 on Monday, hitting $14.18. The company's stock had a trading volume of 864,567 shares, compared to its average volume of 1,032,457. Sage Therapeutics has a fifty-two week low of $10.92 and a fifty-two week high of $59.99. The firm's fifty day moving average price is $18.56 and its 200-day moving average price is $20.65. The stock has a market capitalization of $853.38 million, a price-to-earnings ratio of -1.69 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The business had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period in the previous year, the firm posted ($2.46) EPS. The firm's revenue for the quarter was up 139.4% on a year-over-year basis.

Institutional Trading of Sage Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas boosted its position in Sage Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 15,278 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 698 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 748 shares in the last quarter. CWM LLC boosted its position in Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 883 shares in the last quarter. Inspire Investing LLC boosted its position in Sage Therapeutics by 8.4% in the third quarter. Inspire Investing LLC now owns 15,049 shares of the biopharmaceutical company's stock valued at $310,000 after buying an additional 1,169 shares in the last quarter. Finally, Swiss National Bank boosted its position in Sage Therapeutics by 1.0% in the third quarter. Swiss National Bank now owns 118,200 shares of the biopharmaceutical company's stock valued at $2,433,000 after buying an additional 1,200 shares in the last quarter. Institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.